CMPX · Compass Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Thomas J. Schuetz Chief Executive Officer | ▼ Sell | Tax Withholding | 6,603,336 Shares held | 2/8/2026 | View profile |
| Bisker-Leib Vered Chief Operating Officer | ▼ Sell | Tax Withholding | 3,124,426 Shares held | 2/8/2024 | View profile |
| Barry Shin CFO | ▲ Buy | Grant | 525,000 Shares held | 1/2/2026 | View profile |
| Neil Lerner Chief Accounting Officer | ▲ Buy | Open Market | 420,000 Shares held | 10/1/2026 | View profile |
| Jonathan Anderman Gen Counsel & Corporate Sec | ▲ Buy | Grant | 196,000 Shares held | 4/29/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▼ Sell | Open Market | 0 Shares held | 4/9/2025 | View profile |
| Carl L. Gordon Director | ▼ Sell | Open Market | 0 Shares held | 4/9/2025 | View profile |
Transaction History
| Neil Lerner | ▲ Buy | Open Market | 20,000 | $18K | 10/1/2026 |
| Neil Lerner | ▲ Buy | Open Market | 2,500 | $3K | 9/24/2026 |
| Jonathan Anderman | ▲ Buy | Grant | 25,000 | $47K | 4/29/2026 |
| Neil Lerner | ▲ Buy | Grant | 15,000 | $28K | 4/29/2026 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 36,687 | $239K | 2/8/2026 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 46,777 | $250K | 1/9/2026 |
| Barry Shin | ▲ Buy | Grant | 125,000 | $646K | 1/2/2026 |
| Thomas J. Schuetz | ▲ Buy | Grant | 250,000 | $1.3M | 1/2/2026 |
| Neil Lerner | ▲ Buy | Grant | 62,500 | $323K | 1/2/2026 |
| Jonathan Anderman | ▲ Buy | Grant | 150,000 | $776K | 1/2/2026 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 44,025 | $213K | 11/16/2025 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 10,000 | $21K | 5/27/2025 |
| Carl L. Gordon | ▼ Sell | Open Market | 3,571,428 | $5.7M | 4/9/2025 |
| ORBIMED ADVISORS LLC | ▼ Sell | Open Market | 3,571,428 | $5.7M | 4/9/2025 |
| Neil Lerner | ▲ Buy | Open Market | 20,000 | $28K | 4/7/2025 |
| Jonathan Anderman | ▲ Buy | Open Market | 20,000 | $31K | 4/7/2025 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 41,687 | $146K | 2/8/2025 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 58,054 | $108K | 1/9/2025 |
| Barry Shin | ▲ Buy | Grant | 400,000 | $660K | 12/9/2024 |
| Bisker-Leib Vered | ▼ Sell | Tax Withholding | 49,198 | $71K | 2/8/2024 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 44,782 | $65K | 2/8/2024 |
| Thomas J. Schuetz | ▲ Buy | Grant | 637,500 | $1.2M | 1/9/2024 |
| Bisker-Leib Vered | ▲ Buy | Grant | 1,753,125 | $3.4M | 1/9/2024 |
| Bisker-Leib Vered | ▼ Sell | Tax Withholding | 64,415 | $97K | 11/17/2023 |
| Thomas J. Schuetz | ▼ Sell | Tax Withholding | 44,025 | $66K | 11/17/2023 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 10,000 | $34K | 3/10/2023 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $80K | 2/27/2023 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $77K | 2/15/2023 |
| Bisker-Leib Vered | ▲ Buy | Grant | 400,000 | $0 | 2/8/2023 |
| Thomas J. Schuetz | ▲ Buy | Grant | 500,000 | $0 | 2/8/2023 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $81K | 1/31/2023 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $84K | 1/24/2023 |
| Bisker-Leib Vered | ▼ Sell | Open Market | 2 | $9 | 11/25/2022 |
| Bisker-Leib Vered | ▼ Sell | Open Market | 9,569 | $41K | 11/23/2022 |
| Bisker-Leib Vered | ▼ Sell | Open Market | 14,929 | $63K | 11/22/2022 |
| Bisker-Leib Vered | ▼ Sell | Open Market | 16,035 | $70K | 11/21/2022 |
| Bisker-Leib Vered | ▼ Sell | Open Market | 6,226 | $27K | 11/18/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 402,000 | $1.3M | 11/8/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 402,000 | $1.3M | 11/8/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 10,000 | $23K | 9/28/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $34K | 9/26/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $45K | 9/7/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $42K | 9/1/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $46K | 8/17/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $40K | 8/10/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 15,000 | $39K | 8/1/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $56K | 6/21/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $47K | 6/16/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 30,000 | $69K | 6/13/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 30,000 | $85K | 6/6/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $61K | 6/1/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,000 | $61K | 5/26/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 18,355 | $50K | 5/23/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 20,215 | $50K | 5/17/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 30,722 | $76K | 5/13/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 30,722 | $76K | 5/13/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 97,094 | $228K | 5/12/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 97,094 | $228K | 5/12/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 64,700 | $116K | 5/11/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 64,700 | $116K | 5/11/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 24,447 | $39K | 5/10/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 24,447 | $39K | 5/10/2022 |
| Thomas J. Schuetz | ▲ Buy | Open Market | 27,836 | $50K | 5/10/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 90,712 | $142K | 5/9/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 90,712 | $142K | 5/9/2022 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 10,200 | $17K | 5/6/2022 |
| Carl L. Gordon | ▲ Buy | Open Market | 10,200 | $17K | 5/6/2022 |
| Thomas J. Schuetz | ▲ Buy | Grant | 600,000 | $0 | 11/16/2021 |
| Bisker-Leib Vered | ▲ Buy | Grant | 600,000 | $0 | 11/16/2021 |
| Carl L. Gordon | ▲ Buy | Open Market | 3,571,428 | $12.5M | 11/4/2021 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,785,715 | $6.3M | 11/4/2021 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 3,571,428 | $12.5M | 11/4/2021 |
| Carl L. Gordon | ▲ Buy | Open Market | 1,785,715 | $6.3M | 11/4/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Compass Therapeutics faces analyst downgrades after FDA setback
Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.
Compass Therapeutics faces analyst downgrades after FDA setback. Compass Therapeutics is facing renewed scrutiny following an FDA setback for tovecimig, which H.C. Wainwright described as a risky filing strategy. Several firms, including Citizens, Guggenheim, and Craig-Hallum, lowered their price targets to $4 or $8 while maintaining positive ratings. The stock's RSI is near 20.7, indicating it is currently trading in oversold territory.